1. Priority of SARC studies for selected sub-types

2. Eligibility SARC 003 –Gem/docetaxel –Osteo/Ewings < 2 prior regimens –Chondrosarcoma 0-X prior regimens SARC 006 –AI/IE –1 st line SARC 007 –Perifosine –<3 prior regimens SARC009 –Dasatinib –0-X prior regimens SARC 011 –R1507 –0-X prior regimens

3. Chondrosarcoma 1.SARC 003: gemcitabine and docetaxel in bone sarcomas 2.SARC 007: perifosine in chemotherapy insensitive sarcomas (requires documented disease progression for participation) 3.SARC 009: dasatinib in advanced sarcomas (does not require documented disease progression for participation)

4. Ewings 1.SARC 003: gemcitabine and docetaxel in bone sarcomas 2.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma 3.SARC 009: dasatinib in advanced sarcomas

5. Alveolar soft part sarcoma 1.SARC 007: perifosine in chemotherapy insensitive sarcomas 2.SARC 009: dasatinib in advanced sarcomas 3.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma

6. MPNST 1.SARC 006: chemotherapy in high-grade MPNST 2.SARC 009: dasatinib in advanced sarcomas

7. Rhabdomyosarcoma 1.SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma 2.SARC 009: dasatinib in advanced sarcomas

8. Liposarcoma Extraskeletal Myxoid Chondro SARC 009: dasatinib in advanced sarcomas SARC 011: IGF-1R for refractory/recurrent subtypes of sarcoma

9. SARC Principles Data trumps “BS” –Rhabdomyosarcoma –Ewings OTHERWISE It’s not over till it’s over –009 precedes 011 –003 precedes 007 In God we trust, everyone else pays cash OR You vote with your feet